NCT04535271View on ClinicalTrials.gov

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

September 30, 2028

Study Completion Date

March 30, 2029

Conditions
Leiomyosarcoma
Interventions
DRUG

Trabectedin

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Trial Locations (1)

90403

RECRUITING

Sant P Chawla, Santa Monica

All Listed Sponsors
lead

Sarcoma Oncology Research Center, LLC

OTHER